Neulasta(pegfilgrastim)
Cegfila, Fulphila, Fylnetra, Grasustek, Neulasta, Nyvepria, Pegfilgrastim, Pelgraz, Pelmeg, Stimufend, Udenyca, Ziextenzo (pegfilgrastim) is a protein pharmaceutical. Pegfilgrastim was first approved as Neulasta on 2002-01-31. It is used to treat neutropenia in the USA. It has been approved in Europe to treat neoplasms and neutropenia. The pharmaceutical is active against granulocyte colony-stimulating factor receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
Fulphila, Fylnetra, Neulasta onpro, Nyvepria, Stimufend, Udenyca onbody, Ziextenzo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fulphila | Biologic Licensing Application | 2023-12-05 |
| fylnetra | Biologic Licensing Application | 2025-04-25 |
| neulasta | Biologic Licensing Application | 2025-04-14 |
| nyvepria | Biologic Licensing Application | 2023-06-29 |
| stimufend | Biologic Licensing Application | 2023-10-24 |
| udenyca | Biologic Licensing Application | 2025-08-14 |
| ziextenzo | Biologic Licensing Application | 2022-12-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| neutropenia | — | D009503 | D70 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
pegfilgrastim, Neulasta, Amgen Inc. | |||
| 2122-11-13 | Orphan excl. | ||
pegfilgrastim, Neulasta Onpro, Amgen Inc. | |||
| 2122-11-13 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
| Q5108 | Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg |
| Q5111 | Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg |
| Q5120 | Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg |
| Q5122 | Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg |
Clinical
Clinical Trials
484 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 11 | 52 | 27 | 12 | 12 | 107 |
| Lymphoma | D008223 | — | C85.9 | 18 | 53 | 12 | 7 | 8 | 85 |
| Neutropenia | D009503 | — | D70 | 7 | 22 | 24 | 10 | 11 | 71 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 9 | 19 | 2 | 3 | 5 | 34 |
| Neoplasms | D009369 | — | C80 | 10 | 13 | 4 | 1 | 5 | 32 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 9 | 17 | 5 | 1 | 1 | 27 |
| B-cell lymphoma | D016393 | — | — | 6 | 14 | 6 | 1 | 2 | 25 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 3 | 15 | 6 | 1 | 2 | 23 |
| Chemotherapy-induced febrile neutropenia | D064146 | — | — | — | 6 | 9 | 1 | 6 | 21 |
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 13 | 2 | 1 | 2 | 20 |
Show 15 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 3 | 21 | 7 | — | 3 | 28 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | 14 | 3 | — | 3 | 21 |
| Sarcoma | D012509 | — | — | 6 | 12 | 2 | — | 2 | 19 |
| Hodgkin disease | D006689 | — | C81 | 4 | 9 | 5 | — | — | 15 |
| Plasma cell neoplasms | D054219 | — | — | 1 | 10 | 2 | — | 2 | 14 |
| Recurrence | D012008 | — | — | 5 | 8 | 2 | — | — | 12 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 8 | 4 | — | — | 11 |
| Carcinoma | D002277 | — | C80.0 | 2 | 7 | 2 | — | — | 11 |
| Adenocarcinoma | D000230 | — | — | 3 | 5 | 1 | — | 1 | 10 |
| Triple negative breast neoplasms | D064726 | — | — | 4 | 6 | 2 | — | — | 9 |
Show 33 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | 9 | — | — | — | 9 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 5 | 2 | — | — | 2 | 9 |
| Burkitt lymphoma | D002051 | — | C83.7 | 2 | 7 | — | — | — | 7 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 4 | 5 | — | — | — | 7 |
| Rhabdomyosarcoma | D012208 | — | — | 3 | 4 | — | — | — | 6 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 4 | 3 | — | — | — | 6 |
| Central nervous system neoplasms | D016543 | — | — | 2 | 5 | — | — | — | 6 |
| Follicular lymphoma | D008224 | — | C82 | 3 | 4 | — | — | — | 6 |
| Head and neck neoplasms | D006258 | — | — | 3 | 3 | — | — | — | 5 |
| Transitional cell carcinoma | D002295 | — | — | — | 5 | — | — | — | 5 |
Show 76 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 17 | — | — | — | 1 | 18 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 2 | — | — | — | 2 | 4 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | — | — | — | — | 2 |
| Coronary artery disease | D003324 | — | I25.1 | 1 | — | — | — | 1 | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | — | — | — | 1 | 2 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 1 | — | — | — | — | 1 |
| Vaccine immunogenicity | D000071497 | — | — | 1 | — | — | — | — | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 1 | — | — | — | — | 1 |
Show 14 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pheochromocytoma | D010673 | — | — | — | — | — | — | 2 | 2 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | — | — | — | 2 | 2 |
| Syndrome | D013577 | — | — | — | — | — | — | 1 | 1 |
| Hemophagocytic lymphohistiocytosis | D051359 | — | D76.1 | — | — | — | — | 1 | 1 |
| Coronary disease | D003327 | — | — | — | — | — | — | 1 | 1 |
| Bone nails | D001858 | — | — | — | — | — | — | 1 | 1 |
| Patient reported outcome measures | D000071066 | — | — | — | — | — | — | 1 | 1 |
| Patient satisfaction | D017060 | — | — | — | — | — | — | 1 | 1 |
| Patient preference | D057240 | — | — | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pegfilgrastim |
| INN | pegfilgrastim |
| Description | Granulocyte colony-stimulating factor precursor (G-CSF) (Pluripoietin) |
| Classification | Protein |
| Drug class | PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer; colony-stimulating factors: granulocyte colony-stimulating factors (G-CSF) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201568 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00019 |
| UNII ID | 3A58010674 (ChemIDplus, GSRS) |
Target
Agency Approved
CSF3R
CSF3R
Organism
Homo sapiens
Gene name
CSF3R
Gene synonyms
GCSFR
NCBI Gene ID
Protein name
granulocyte colony-stimulating factor receptor
Protein synonyms
CD114, CD114 antigen, colony stimulating factor 3 receptor (granulocyte), G-CSF receptor, G-CSF-R
Uniprot ID
Mouse ortholog
Csf3r (12986)
granulocyte colony-stimulating factor receptor (P40223)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Udenyca – Coherus Oncology
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Neulasta – Amgen
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,329 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
92,786 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use